Dexcom Inc. defeated investor allegations the glucose monitor maker overhyped its growth potential before a nearly 41% stock drop, a federal judge ruled.

DexCom Inc. closed 34.58% short of its 52-week high of $132.26, which the company reached on May 17th.

Shares of DexCom Inc. DXCM shed 1.11% to $84.11 Tuesday, on what proved to be an all-around mixed trading session for the ...

The medical instruments industry is currently undergoing a transformative phase, thanks to the rapid adoption of generative ...

After this recent quarterly performance and the resultant increase in stock price, an important question arises: is DXCM ...

Dexcom (Nadsaq:DXCM) shares rose after hours today on first-quarter results that came in mixed compared to the consensus ...

SAN DIEGO, May 13, 2025--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose biosensing, today announced the promotion of Jake Leach to president ...

The stock surged. Revenue of $1.04 billion topped analysts’ calls for $1.02 billion, according to FactSet. The figure ...

DexCom, Inc. (NASDAQ: DXCM) has once again demonstrated its formidable position in the continuous glucose monitoring (CGM) ...

So even in these challenging times, it's a good idea to look for stocks worth investing in for the next decade and beyond.

The Oura Ring 4 is rapidly becoming the center piece of your efforts to lead a healthier life, and the introduction of two ...